Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at tumor cells · developed by IOVANCE BIOTHERAPEUTICS
IOV-4001 is an autologous tumor-infiltrating lymphocyte (TIL) therapy with the PD-1 gene disrupted using TALEN gene editing. The engineered TILs are expanded ex vivo and reinfused to induce T-cell-mediated killing of tumor cells. It is studied in melanoma and non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05361174 | Phase 1/2 | Unresectable Melanoma | Recruiting | IOVA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic MelanomaStage III Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerUnresectable Melanoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the IOVA page.
See IOVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IOVA catalysts and pipeline →